CATALYSTSeekingAlpha • 1d ago
Gilead Sciences: Why I Remain Bullish After Q3Gilead Sciences had a strong Q3, while successfully shifting its R&D focus from HIV to the immunology market. Read why GILD stock is a buy.
Why GSK Stock slipped -0.12% Today — RQD Quant Desk Flash
$48.68 -0.12% NYSE • Public Delayed / 60s Snapshot
GSK plc American (GSK) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C+ • HOLD / WATCH
Cap $98.47B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+3.6% Base Target
WHALE OPTIONS TUG-OF-WAR:53% Call Buyers ($9.3M)
47% PutsMax Pain: $48.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GSK Stock slipped -0.12% Today — RQD Quant Desk Flash
GSK plc American (GSK) slipped -0.12% to $48.68 as options desks priced 53% call premium vs. 47% put protection around the $48 max-pain magnet. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 18% of its 52-week range ($45.81 – $61.7) with RSI-14 at 51.2 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $9.3M in bullish call flow vs. $8.4M in put flow (Put/Call 0.90x, implied earnings swing ±6.7%).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 41% gross margin and $2.2B annual free cash flow.
Live GSK Headlines & Catalysts
RISK WATCHSeekingAlpha • 2d ago
GSK: The Gas Pedal Is Still Down, But Bumps AheadGSK stock remains a Buy despite Q3 misses, with Specialty Medicines growth, pipeline momentum, valuation upside, and key risks to watch. See more here.
RISK WATCHBenzinga • 2d ago
Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.
CATALYSTYahoo • 2d ago
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
MARKET WIREYahoo • 2d ago
Chiesi Group appoints Paolo Paoletti to its Board of DirectorsPARMA, Italy, October 29, 2026--Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an
RISK WATCHYahoo • 2d ago
GSK (LSE:GSK) Shares Dropped, So What Is Behind The Latest Attention?GSK (LSE:GSK) has released third quarter figures that present a mixed picture. Sales reached £8,887 million, while net income declined to £1,543 million compared with £2,013 million a year earlier. The latest figures lan
CATALYSTYahoo • 3d ago
Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
MARKET WIREYahoo • 3d ago
Glaxo: Q3 Earnings SnapshotLONDON (AP) — LONDON (AP) — GSK plc (GSK) on Wednesday reported third-quarter net income of $2.On a per-share basis, the London-based company said it had net income of $1.
CATALYSTYahoo • 3d ago
What GSK (GSK) Said on Its Q3 Earnings CallGSK (NYSE:GSK) reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while c
MARKET WIREYahoo • 3d ago
GSK Fumbles On Vaccines, HIV — Reversing An 11% Pre-Earnings RunRevenue from GSK's vaccines came up short Wednesday, including the drugmaker's household name shot, Shingrix.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live GSK Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
GSK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.35%▼ DESCENDING CHANNEL
2026-10-30O $49.84H $50.28L $49.25C $49.51VOL 4.77M
RES: $51.01SUP: $44.63SMA50: $49.43SMA200: $52.34
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GSK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GSK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GSK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GSK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
GSK Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GSK stock moving today?
Why GSK Stock slipped -0.12% Today — RQD Quant Desk Flash. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.